دورية أكاديمية
Longitudinal monitoring of Torque Teno virus DNAemia in kidney transplant recipients correlates with long-term complications of inadequate immunosuppression.
| العنوان: | Longitudinal monitoring of Torque Teno virus DNAemia in kidney transplant recipients correlates with long-term complications of inadequate immunosuppression. |
|---|---|
| المؤلفون: | Chauvelot L; Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Groupement Hospitalier Centre, Lyon, France.; CIRI, Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France., Barba T; Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Groupement Hospitalier Centre, Lyon, France.; Lyon-Est Medical Faculty, Claude Bernard University (Lyon 1), Lyon, France.; Department of Internal Medicine, Hospices Civils de Lyon, Groupement Hospitalier Centre, Lyon, France., Saison C; CIRI, Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.; French National Blood Service (EFS), HLA Laboratory, Lyon, France., Siska E; BioMérieux SA, 138, Rue Louis PASTEUR, Parc Technologique Delta Sud, Verniolle, France., Kulifaj D; BioMérieux SA, 138, Rue Louis PASTEUR, Parc Technologique Delta Sud, Verniolle, France., Bakker SJL; Department of Internal Medicine, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands., Koenig A; Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Groupement Hospitalier Centre, Lyon, France.; CIRI, Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.; Lyon-Est Medical Faculty, Claude Bernard University (Lyon 1), Lyon, France., Rabeyrin M; Department of Pathology, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France., Buron F; Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Groupement Hospitalier Centre, Lyon, France., Picard C; Department of Pathology, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France., Dijoud F; Department of Pathology, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France., Manière L; Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Groupement Hospitalier Centre, Lyon, France., Lina B; CIRI, Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France., Morelon E; Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Groupement Hospitalier Centre, Lyon, France.; CIRI, Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.; Lyon-Est Medical Faculty, Claude Bernard University (Lyon 1), Lyon, France., Dubois V; CIRI, Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.; French National Blood Service (EFS), HLA Laboratory, Lyon, France., Thaunat O; Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Groupement Hospitalier Centre, Lyon, France.; CIRI, Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.; Lyon-Est Medical Faculty, Claude Bernard University (Lyon 1), Lyon, France. |
| المصدر: | Journal of medical virology [J Med Virol] 2024 Jul; Vol. 96 (7), pp. e29806. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print Cited Medium: Internet ISSN: 1096-9071 (Electronic) Linking ISSN: 01466615 NLM ISO Abbreviation: J Med Virol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York Ny : Wiley-Liss Original Publication: New York, Liss. |
| مواضيع طبية MeSH: | Torque teno virus*/genetics , Kidney Transplantation*/adverse effects , DNA, Viral*/blood , Transplant Recipients* , DNA Virus Infections*/virology , DNA Virus Infections*/blood , DNA Virus Infections*/immunology , Immunosuppression Therapy*/adverse effects, Humans ; Male ; Female ; Middle Aged ; Adult ; Longitudinal Studies ; Aged ; Graft Rejection ; Immunosuppressive Agents/therapeutic use ; Immunosuppressive Agents/adverse effects ; Cohort Studies ; Viremia |
| مستخلص: | Optimization of individual immunosuppression, which reduces the risks of both graft loss and patients' death, is considered the best approach to improve long-term outcomes of renal transplantation. Torque Teno Virus (TTV) DNAemia has emerged as a potential biomarker reflecting the depth of therapeutic immunosuppression during the initial year post-transplantation. However, its efficacy in long-term monitoring remains uncertain. In a cohort study involving 34 stable kidney transplant recipients and 124 healthy volunteers, we established lower and upper TTV DNAemia thresholds (3.75-5.1 log10 cp/mL) correlating with T-cell activatability, antibody response against flu vaccine, and risk for subsequent serious infections or cancer over 50 months. Validation in an independent cohort of 92 recipients confirmed that maintaining TTV DNAemia within this range in >50% of follow-up time points was associated with reduced risks of complications due to inadequate immunosuppression, including de novo DSA, biopsy-proven antibody-mediated rejection, graft loss, infections, or cancer. Multivariate analysis highlighted "in-target" TTV DNAemia as the sole independent variable significantly linked to decreased risk for long-term complications due to inadequate immunosuppression (odds ratio [OR]: 0.27 [0.09-0.77]; p = 0.019). Our data suggest that the longitudinal monitoring of TTV DNAemia in kidney transplant recipients could help preventing the long-term complications due to inadequate immunosuppression. (© 2024 Wiley Periodicals LLC.) |
| References: | Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725‐1730. doi:10.1056/NEJM199912023412303. Fishman JA. Infection in solid‐organ transplant recipients. N Engl J Med. 2007;357(25):2601‐2614. doi:10.1056/NEJMra064928. Engels EA, Pfeiffer RM, Fraumeni JF, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891‐1901. doi:10.1001/jama.2011.1592. Bouamar R, Shuker N, Hesselink DA, et al. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized‐controlled clinical trials(†). Am J Transplant. 2013;13(5):1253‐1261. doi:10.1111/ajt.12191. Dahdal S, Saison C, Valette M, et al. Residual activatability of circulating Tfh17 predicts humoral response to thymodependent antigens in patients on therapeutic immunosuppression. Front Immunol. 2019;9:3178. doi:10.3389/fimmu.2018.03178. Keller F, Sommerer C, Giese T, Zeier M, Schröppel B. Correlation between pharmacokinetics of tacrolimus and pharmacodynamics on NFAT‐regulated gene expression in stable kidney transplant recipients. Clin Nephrol. 2017;87(2):93‐99. doi:10.5414/CN108893. Yatscoff RW, Aspeslet LJ, Gallant HL. Pharmacodynamic monitoring of immunosuppressive drugs. Clin Chem. 1998;44(2):428‐432. Thaunat O. Finding the safe place between the hammer and the anvil: sounding the depth of therapeutic immunosuppression. Kidney Int. 2015;88(6):1226‐1228. doi:10.1038/ki.2015.268. Doberer K, Schiemann M, Strassl R, et al. Torque teno virus for risk stratification of graft rejection and infection in kidney transplant recipients—a prospective observational trial. Am J Transplant. 2020;20(8):2081‐2090. doi:10.1111/ajt.15810. Eldar‐Yedidia Y, Ben‐Shalom E, Hillel M, et al. Association of post‐transplantation anellovirus viral load with kidney transplant rejection in children. Pediatr Nephrol. 2022;37(8):1905‐1914. doi:10.1007/s00467-021-05336-w. Fernández‐Ruiz M, Albert E, Giménez E, et al. Monitoring of alphatorquevirus DNA levels for the prediction of immunosuppression‐related complications after kidney transplantation. Am J Transplant. 2019;19(4):1139‐1149. doi:10.1111/ajt.15145. Maggi F, Focosi D, Statzu M, et al. Early post‐transplant torquetenovirus viremia predicts cytomegalovirus reactivations in solid organ transplant recipients. Sci Rep. 2018;8(1):15490. doi:10.1038/s41598-018-33909-7. Strassl R, Doberer K, Rasoul‐Rockenschaub S, et al. Torque teno virus for risk stratification of acute biopsy‐proven alloreactivity in kidney transplant recipients. J Infect Dis. 2019;219(12):1934‐1939. doi:10.1093/infdis/jiz039. Coemans M, Callemeyn J, Naesens M. Long‐term survival after kidney transplantation. N Engl J Med. 2022;386(5):497‐500. doi:10.1056/NEJMc2115207. Halloran PF, Chang J, Famulski K, et al. Disappearance of T cell‐mediated rejection despite continued antibody‐mediated rejection in late kidney transplant recipients. J Am Soc Nephrol. 2015;26(7):1711‐1720. doi:10.1681/ASN.2014060588. Mayrdorfer M, Liefeldt L, Wu K, et al. Exploring the complexity of death‐censored kidney allograft failure. J Am Soc Nephrol. 2021;32(6):1513‐1526. doi:10.1681/ASN.2020081215. Pouliquen E, Koenig A, Chen CC, et al. Recent advances in renal transplantation: antibody‐mediated rejection takes center stage. F1000Prime Rep. 2015;7:51. doi:10.12703/P7-51. Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody‐mediated rejection and nonadherence. Am J Transplant. 2012;12(2):388‐399. doi:10.1111/j.1600-6143.2011.03840.x. Terasaki PI. A personal perspective: 100‐year history of the humoral theory of transplantation. Transplantation. 2012;93(8):751‐756. doi:10.1097/TP.0b013e3182483713. Wiebe C, Gibson IW, Blydt‐Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor‐specific HLA antibody post kidney transplant. Am J Transplant. 2012;12(5):1157‐1167. doi:10.1111/j.1600-6143.2012.04013.x. Ruenroengbun N, Numthavaj P, Sapankaew T, et al. Efficacy and safety of conventional antiviral agents in preventive strategies for cytomegalovirus infection after kidney transplantation: a systematic review and network meta‐analysis. Transpl Int. 2021;34(12):2720‐2734. doi:10.1111/tri.14122. Acuna SA, Fernandes KA, Daly C, et al. Cancer mortality among recipients of solid‐organ transplantation in Ontario, Canada. JAMA Oncology. 2016;2(4):463‐469. doi:10.1001/jamaoncol.2015.5137. Bonabaud M, Kulifaj D, Meynier F, et al. First step of the validation of the TTV‐R‐GENE® as a standardized tool for TTV detection and monitoring in serum. Presented at: European Society for Clinical Virology; September 2, 2023; Milano, Italy. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351(26):2715‐2729. doi:10.1056/NEJMra033540. Dahdal S, Saison C, Valette M, et al. Residual activatability of circulating Tfh17 predicts humoral response to thymodependent antigens in patients on therapeutic immunosuppression. Front Immunol. 2018;9:3178. doi:10.3389/fimmu.2018.03178. Morita R, Schmitt N, Bentebibel SE, et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity. 2011;34(1):108‐121. doi:10.1016/j.immuni.2010.12.012. Smith RN, Kawai T, Boskovic S, et al. Chronic antibody mediated rejection of renal allografts: pathological, serological and immunologic features in nonhuman primates. Am J Transplant. 2006;6(8):1790‐1798. doi:10.1111/j.1600-6143.2006.01351.x. Shiffler RE. Maximum Z scores and outliers. Am Stat. 1988;42(1):79‐80. doi:10.1080/00031305.1988.10475530. Focosi D, Spezia PG, Macera L, et al. Assessment of prevalence and load of torquetenovirus viraemia in a large cohort of healthy blood donors. Clin Microbiol Infect. 2020;26(10):1406‐1410. doi:10.1016/j.cmi.2020.01.011. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(suppl. 3):S1‐155. doi:10.1111/j.1600-6143.2009.02834.x. Schanen BC, De Groot AS, Moise L, et al. Coupling sensitive in vitro and in silico techniques to assess cross‐reactive CD4(+) T cells against the swine‐origin H1N1 influenza virus. Vaccine. 2011;29(17):3299‐3309. doi:10.1016/j.vaccine.2011.02.019. Naesens M, Budde K, Hilbrands L, et al. Surrogate endpoints for late kidney transplantation failure. Transpl Int. 2022;35:10136. doi:10.3389/ti.2022.10136. Bestard O, Cruzado JM, Lucia M, et al. Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation. Kidney Int. 2013;84(6):1226‐1236. doi:10.1038/ki.2013.236. Hope CM, Troelnikov A, Hanf W, et al. Peripheral natural killer cell and allo‐stimulated T‐cell function in kidney transplant recipients associate with cancer risk and immunosuppression‐related complications. Kidney Int. 2015;88(6):1374‐1382. doi:10.1038/ki.2015.237. Luque S, Lúcia M, Melilli E, et al. Value of monitoring circulating donor‐reactive memory B cells to characterize antibody‐mediated rejection after kidney transplantation. Am J Transplant. 2019;19(2):368‐380. doi:10.1111/ajt.15055. Sawitzki B, Schlickeiser S, Reinke P, Volk HD. Monitoring tolerance and rejection in organ transplant recipients. Biomarkers. 2011;16(suppl 1):S42‐S50. doi:10.3109/1354750X.2011.578754. Bendinelli M, Pistello M, Maggi F, Fornai C, Freer G, Vatteroni ML. Molecular properties, biology, and clinical implications of TT virus, a recently identified widespread infectious agent of humans. Clin Microbiol Rev. 2001;14(1):98‐113. doi:10.1128/CMR.14.1.98-113.2001. Görzer I, Jaksch P, Kundi M, Seitz T, Klepetko W, Puchhammer‐Stöckl E. Pre‐transplant plasma Torque Teno virus load and increase dynamics after lung transplantation. PLoS One. 2015;10(3):e0122975. doi:10.1371/journal.pone.0122975. De Vlaminck I, Khush KK, Strehl C, et al. Temporal response of the human virome to immunosuppression and antiviral therapy. Cell. 2013;155(5):1178‐1187. doi:10.1016/j.cell.2013.10.034. Görzer I, Haupenthal F, Maggi F, et al. Validation of plasma Torque Teno viral load applying a CE‐certified PCR for risk stratification of rejection and infection post kidney transplantation. J Clin Virol. 2023;158:105348. doi:10.1016/j.jcv.2022.105348. van Rijn A, Roos R, Dekker F, Rotmans J, Feltkamp M. Torque teno virus load as marker of rejection and infection in solid organ transplantation—a systematic review and meta‐analysis. Rev Med Virol. 2023;33(1):e2393. doi:10.1002/rmv.2393. van Rijn AL, Wunderink HF, Sidorov IA, et al. Torque teno virus loads after kidney transplantation predict allograft rejection but not viral infection. J Clin Virol. 2021;140:104871. doi:10.1016/j.jcv.2021.104871. Schiemann M, Puchhammer‐Stöckl E, Eskandary F, et al. Torque teno virus load‐inverse association with antibody‐mediated rejection after kidney transplantation. Transplantation. 2017;101(2):360‐367. doi:10.1097/TP.0000000000001455. Gore EJ, Gomes‐Neto AW, Wang L, et al. Torquetenovirus serum load and long‐term outcomes in renal transplant recipients. J Clin Med. 2020;9(2):440. doi:10.3390/jcm9020440. Jaksch P, Görzer I, Puchhammer‐Stöckl E, Bond G. Integrated immunologic monitoring in solid organ transplantation: the road toward torque teno virus‐guided immunosuppression. Transplantation. 2022;106(10):1940‐1951. doi:10.1097/TP.0000000000004153. Haupenthal F, Rahn J, Maggi F, et al. A multicentre, patient‐ and assessor‐blinded, non‐inferiority, randomised and controlled phase II trial to compare standard and torque teno virus‐guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT. Trials. 2023;24(1):213. doi:10.1186/s13063-023-07216-0. |
| معلومات مُعتمدة: | bioMérieux; Luc Chauvelot received a fellowship "année recherche" from the Hospices Civils de Lyon. Thomas Barba is supported by INSERM (poste accueil 2016), and the Hospices Civils de Lyon. Olivier Thaunat is supported by the Fondation pour la Recherche médicale (PME20180639518), and the Etablissement français du Sang |
| فهرسة مساهمة: | Keywords: DSA; TTV; biomarker; cancer; infection; kidney transplantation; therapeutic immunosuppression |
| المشرفين على المادة: | 0 (DNA, Viral) 0 (Immunosuppressive Agents) |
| تواريخ الأحداث: | Date Created: 20240715 Date Completed: 20240715 Latest Revision: 20240715 |
| رمز التحديث: | 20240715 |
| DOI: | 10.1002/jmv.29806 |
| PMID: | 39007420 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1096-9071 |
|---|---|
| DOI: | 10.1002/jmv.29806 |